Psoriatic arthritis is an inflammatory musculoskeletal disease affecting almost a third of patients with psoriasis. Clinical presentations are complex and varied and include peripheral arthritis, axial disease, dactylitis, and enthesitis,…
Psoriatic arthritis (PsA) is a chronic systemic inflammatory disorder characterized by joint and entheseal inflammation with a prevalence of 0.05% to 0.25% of the population and 6% to 41% of…
Christopher T. Ritchlin, MD, MPH, Editor It is hard to believe that little more than 40 years have elapsed since psoriatic arthritis was first described as a separate entity, HLAB27…
Michael H. Weisman, MD, Consulting Editor Chris Ritchlin has done a remarkable job assembling the expertise necessary to put together a timely comprehensive review of Psoriatic Arthritis. We learn how…
Glucocorticoid-induced osteoporosis (GIOP) is one of the most common and serious adverse effects associated with glucocorticoid use. This article highlights GIOP pathophysiology, epidemiologic associations, effective treatment, and lifestyle modifications that…
Corticosteroids are frequently used to treat rheumatic diseases. Their use comes with several well-established risks, including osteoporosis, avascular necrosis, glaucoma, and diabetes. The risk of infection is of utmost concern…
Corticosteroids are the drug of choice for the treatment of sarcoidosis. Because the natural course of sarcoidosis may be self-limiting and/or cause no long-term harm, treatment is not mandatory. Corticosteroids…
Idiopathic inflammatory myopathies (IIMs) involve inflammation of the muscles and are classified by the patterns of presentation and immunohistopathologic features on skin and muscle biopsy into 4 categories: dermatomyositis, polymyositis,…
Targeted interventional delivery of corticosteroids remains a mainstay of treatment for spinal pain syndromes because this approach has a wider therapeutic index than other approaches. The best evidence for analgesic…
Glucocorticoids (GCs) have been the cornerstone of antineutrophil cytoplasmic antibody–associated vasculitis (AAV) therapy since their advent in the 1950s. There is considerable variation in their use, both with respect to…
